American Society of Hirudotherapy

Heparin-induced thrombocytopenia--recognition and treatment.

Research article published in AORN journal (2003)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportClinical TrialsDrug DevelopmentMiller · AORN journal, 2003

Abstract

Heparin, an important agent for the prophylaxis and treatment of venous and arterial thromboembolism, also can cause heparin-induced thrombocytopenia (HIT). This medication-induced immune-mediated syndrome is characterized by thrombocytopenia and life- or limb-threatening thrombotic events. The initial presentation of HIT is a decrease in platelet count with or without thrombosis. Heparin-induced thrombocytopenia frequently is overlooked in hospital settings, and it must be distinguished from other causes of thrombocytopenia. New therapies include the use of direct thrombin inhibitors argatroban and hirudin.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnticoagulantsArginineHeparinHirudin TherapyHumansNursing AssessmentPerioperative NursingPipecolic AcidsSulfonamidesThrombocytopenia

Summary

Heparin, an important agent for the prophylaxis and treatment of venous and arterial thromboembolism, also can cause heparin-induced thrombocytopenia (HIT). This medication-induced immune-mediated syndrome is characterized by thrombocytopenia and life- or limb-threatening thrombotic events.

Why This Matters for Hirudotherapy

This article reviews the recognition and treatment of heparin-induced thrombocytopenia (HIT), an immune-mediated syndrome characterized by thrombocytopenia and potentially life- or limb-threatening thrombosis, and notes that new therapies include direct thrombin inhibitors argatroban and hirudin. The explicit mention of hirudin as a therapeutic agent directly connects this article to ASH's domain, as hirudin is the prototypical anticoagulant from the medicinal leech secretome. The relevance is clear: hirudin is positioned as a treatment option for a serious prothrombotic disorder. However, the abstract is brief and general, does not provide clinical outcome data, dosing, or comparative efficacy for hirudin, and does not address hirudotherapy (leech application) itself — only the isolated agent.

Citation

Heparin-induced thrombocytopenia--recognition and treatment.

Miller · AORN journal, 2003

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.